Cytarabine data

CHMX (Fort Lee, N.J.) said that a Phase I/II trial in 25 patients of Cytarabine did not show sufficient efficacy against genital warts to justify further development of the injectable formulation.

The company declined to disclose further data from the trial, and said it is still deciding whether to pursue developing a formulation that would resist metabolic degradation. CHMX believes that metabolism of the drug is responsible for the lack of efficacy. ...